Vaccines targeting SARS-CoV-2 tested in humans
- 24 August 2020
- journal article
- editorial
- Published by Springer Nature in Nature Medicine
- Vol. 26 (9) , 1336-1338
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportNew England Journal of Medicine, 2020
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsNature, 2020
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialThe Lancet, 2020
- Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccinesVaccine, 2020
- Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trialThe Lancet Infectious Diseases, 2019
- mRNA vaccines — a new era in vaccinologyNature Reviews Drug Discovery, 2018
- Emerging viral diseases from a vaccinology perspective: preparing for the next pandemicNature Immunology, 2017
- Chimpanzee adenoviral vectors as vaccines for outbreak pathogensHuman Vaccines & Immunotherapeutics, 2017
- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS VirusPLOS ONE, 2012
- A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trialVaccine, 2008